Carcinogenesis, Teratogenesis & Mutagenesis ›› 2016, Vol. 28 ›› Issue (1): 73-76.doi: 10.3969/j.issn.1004-616x.2016.01.016
Previous Articles Next Articles
Received:2015-09-11
Revised:2015-09-25
Online:2016-01-31
Published:2016-01-31
CLC Number:
Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks
| [1] McIlwain CC,Townsend DM,Tew KD. Glutathione S-transferase polymorphisms:cancer incidence and therapy[J]. Oncogene,2006 25(11):1639-1648. [2] Chen HC,Cao YF,Hu WX,et al. Genetic polymorphisms of phase II metabolic enzymes and lung cancer susceptibility in a population of Central South China[J]. Dis Markers,2006,22(3):141-152. [3] Singh H,Sachan R,Devi S,et al. Association of GSTM1,GSTT1 and GSTM3 gene polymorphisms and susceptibility to cervical cancer in a North Indian population[J]. Am J Obstet Gynecol,2008,198(3): 303-306. [4] Townsend DM,Tew KD. The role of glutathione-S transferase in anti-cancer drug resistance[J]. Oncogene,2003,22:7369-7375. [5] Di Pietro G,Magno LA,Rios-Santos F. Glutathione S-transferases: an overview in cancer research[J]. Expert Opin Drug Metab Toxicol 2010,6(2):153-170. [6] Xu S,Wang Y,Roe B,et al. Characterization of the human class Mu glutathione S-transferase gene cluster and the GSTM1 deletion[J]. J Biol Chem,1998,273(6):3517-3527. [7] Smith CM,Kelsey KT,Wiencke JK,et al. Inherited glutathione-S-transferase deficiency is a risk factor for pulmonary asbestosis[J]. Cancer Epidemiol Biomarkers Prev,1994,3(6):471-477. [8] Parl F. A need for true GSTM1 and GSTT1 genotyping[J]. Cancer Epidemiol Biomarkers Prev,2009,18(10):2793. [9] Roodi N,Dupont WD,Moore JH. et al. Association of homozygous wild-type glutathione S-transferase M1 genotype with increased breast cancer risk[J]. Cancer Res,2004,64(4):1233-1236. [10] Sprenger R,Schlagenhaufer R,Kerb R. Characterization of the glutathione S-transferase GSTT1 deletion:discrimination of all genotypes by polymerase chain reaction indicates a trimodular genotype phenotype correlation[J]. Pharmacogenetics,2000,10:557-65. [11] Yu KD,Di GH,Fan L,et al. A functional polymorphism in the promoter region of GSTM1 implies a complex role for GSTM1 in breast cancer [J]. FASEB J,2009,23(7):2274-2287. [12] Ueda M,Toji E,Nunobiki O,et al. Germline polymorphisms of glutathione-S-transferase GSTM1,GSTT1 and p53 codon 72 in cervical carcinogenesis[J]. Hum Cell,2010,23(4):119-125. [13] Palma S,Novelli F,Padua L,et al. Interaction between glutathione S-transferase polymorphisms,smoking habit,and HPV infection in cervical cancer risk[J]. J Cancer Res Clin Oncol,2010,136(7): 1101-1109. [14] Kiran B,Karkucak M,Ozan H,et al. GST (GSTM1,GSTT1,and GSTP1) polymorphisms in the genetic susceptibility of Turkish patients to cervical cancer[J]. J Gynecol Oncol,2010,21 (3):169-173. [15] Natphopsuk S,Settheetham-Ishida W,Settheetham D. Lack of participation of the GSTM1 polymorphism in cervical cancer development in Northeast Thailand[J]. Asian Pac J Cancer Prev,2015,16(5): 1935-1937. [16] Hasan S,Hameed A,Saleem S. The association of GSTM1 and GSTT1 polymorphisms with squamous cell carcinoma of cervix in Pakistan[J]. Tumour Biol,2015,36(7):5195-5199. [17] Economopoulos KP,Choussein S,Vlahos NF. GSTM1 polymorphism GSTT1 polymorphism,and cervical cancer risk:a meta-analysis[J]. Int J Gynecol Cancer,2010,20(9):1576-1580 [18] Au WW,Sierra-Torres CH,Tyring SK. Acquired and genetic susceptibility to cervical cancer[J]. Mutat Res,2003,544(2/3):361-364. [19] 周 芩,王金桃,邵淑丽,等. GSTM1及GSTT 1基因多态性与宫颈癌关系的研究[J]. 现代预防医学,2006,33(3):269-271. [20] 宋广叶,宋志宇,许瑾丽,等. GSTM1基因多态性与山西地区宫颈癌遗传易感性关系的研究[J]. 中华肿瘤防治杂志,2008,15(14): 1054-1056. [21] 刘 瑶,马文静,刘 清,等. GSTM1、CYP2E1基因多态性与新疆维吾尔族妇女宫颈癌及癌前病变关联性的研究[J]. 现代妇产科进展,2009,18(11):840-843. [22] Sobti RC,Kaur S,Kaur P,et al. Interaction of passive smoking with GST (GSTM1,GSTT1,and GSTP1) genotypes in the risk of cervical cancer in India[J]. Cancer Genet Cytogenet,2006,166:117-123. [23] Baxter SW,Thomas EJ,Campbell IG. GSTM1 null polymorphism and susceptibility to endometriosis and ovarian cancer[J]. Carcinogenesis 2001,22(1):63-65. [24] Spurdle AB,Webb PM,Purdie DM,et al. Polymorphisms at the glutathione S-transferase GSTM1,GSTT1 and GSTP1 loci:risk of ovarian cancer by histological subtype[J]. Carcinogenesis,2001 22(1):67-72. [25] Gates MA,Tworoger SS,Terry KL,et al. Talc use,variants of the GSTM1,GSTT1,and NAT2 genes,and risk of epithelial ovarian cancer[J]. Cancer Epidemiol Biomarkers Prev,2008,17(9):2436-2444. [26] Delort L,Chalabi N,Satih S,et al. Association between genetic polymorphisms and ovarian cancer risk[J]. Anticancer Res,2008 28(5B):3079-3081. [27] Tecza K,Pamula-Pilat J,Kolosza Z et al. Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy[J]. J Exp Clin Cancer Res,2015 34(1):2. [28] Economopoulos KP,Sergentanis TN,Vlahos NF. Glutathione S-transferase M1,T1,and P1 polymorphisms and ovarian cancer risk:a meta-analysis[J]. Int J Gynecol Cancer,2010,20(5):732-737. [29] Legro RS,Kunselman AR,Miller SA,et al. Role of androgens in the growth of endometrial carcinoma:an in vivo animal model[J]. Am J Obstet Gynecol,2001,184(3):303-308. [30] 杜亚飞,李 利,李 炎. GSTM1及GST T1基因多态性与子宫内膜癌易感性的相关性[J]. 中国实用妇科与产科杂志,2010,8(26): 623-626. [31] Karageorgi S,Prescott J,Wong JY,et al. GSTM1 and GSTT1 copy number variation in population-based studies of endometrial cancer risk [J]. Cancer Epidemiol Biomarkers Prev,2011,20(7): 1447-1452. [32] Ashton KA,Proietto A,Otton G,et al. Polymorphisms in genes of the steroid hormone biosynthesis and metabolism pathways and endometrial cancer risk[J]. Cancer Epidemiol,2010,34(3):328-337. [33] Esteller M,Garcia A,Martinez-Palones JM,et al. Susceptibility to endometrial cancer:in?uence of allelism at p53,glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci[J]. Br J Cancer,1997,75(9):1385-1388. [34] Doherty JA,Weiss NS,Freeman RJ,et al. Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer[J]. Cancer Epidemiol Biomarkers Prev,2005,14(2):357-366. [35] Nagle CM,Chenevix-Trench G,Spurdle AB,et al. The role of glutathione-S-transferase polymorphisms in ovarian cancer survival[J]. Eur J Cancer,2007,43(2):283-290. [36] Beeghly A,Katsaros D,Chen H,et al. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival[J]. Gynecol Oncol,2006,100(2):330-337. [37] Kim HS,Kim MK,Chung HH,et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds:a Korean population-based study[J]. Gynecol Oncol,2009,113(2):264-269. [38] Morari EC,Lima AB,Bufalo NE,et al. Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients[J]. J Cancer Res Clin Oncol,2006,132(8):521-528. [39] Soh Y,Goto S,Kitajima M,et al. Nuclear localisation of glutathione S-transferase pi is an evaluation factor for drug resistance in gynaecological cancers[J]. Clin Oncol:R Coll Radiol,2005,17(4): 264-270. [40] 王华英 施达仁 陆洪芬. GST-π与宫颈癌化疗敏感性及预后的关系[J]. 中国癌症杂志,2001,23(4):305-308. |
| [1] | WANG Miao, WANG Quankai, LI Xinwei, MA Shunpeng, WUHAN Baolier, XU Jianning. m6A methylation of mRNAs in glycidyl methacrylate-induced malignant transformation of 16HBE cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 405-409. |
| [2] | GAO Xiaobin, WU Xueliang, WANG Shengjie, SUN Guangyuan, WANG Wenjing, LIANG Feng, ZHAO Yifeng, LIU Zhenxian, ZHANG Yingchun. Expression of TRIM59 and its correlations with clinicopathological features in colorectal cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 446-450. |
| [3] | . [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 470-474. |
| [4] | . [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 475-481. |
| [5] | CUI Zhaoyang, LI Suna, JIANG Xuqian, WANG Yidan, HOU Liying. Activation of the TRAIL death receptor by apigenin for induction of apoptosis in the gastric cancer SGC-7901 cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(1): 32-36. |
| [6] | . [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(1): 72-76. |
| [7] | LI Jinglei, HOU Wei. ceRNA network-based stigmasterolintervention on lung squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 423-429. |
| [8] | SHI Hailin, HE Tianji, LIU Feng, CAI Menghui, GE Bo. Prognostic value of TCGA-database mutation burden in muscle-invasive bladder cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 430-437,443. |
| [9] | . [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 477-480,484. |
| [10] | . [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 485-489. |
| [11] | . [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(4): 317-320,324. |
| [12] | LUAN Yiran, LIU Liyuan, JIAO Long, WANG Yueling, BAI Hanyu, ZOU Naiyi, MA Ming. Clinical significance of miR-429 and Bmi-1 mRNA expression in diffuse large B-cell lymphoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(3): 177-181. |
| [13] | GULZARIA·Aikula, TAN Yao, PALIDA·Apiziaji. Expression of long non-coding RNAs in esophageal squamous cell carcinoma of Kazak nationality in Xinjiang [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(3): 194-197,202. |
| [14] | SHU Zhixiong, WU Chuancheng, WU Xiaoli, LIU Baoying. Relationships between gastric cancer and SNPs of autophagy-related genes on the PI3K/Akt/mTOR pathway [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(2): 118-125,131. |
| [15] | . [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(1): 67-71. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
